In a phase 3 trial, ELITEK given prophylactically (prior to anticancer therapy) maintained normal uric acid levels (≤7.5 mg/dL) in significantly more patients (87%, n=92) vs allopurinol (66%, n=91) between 3 and 7 days after initiation of antihyperuricemic treatment (P=0.001) (primary endpoint).1
Find resources and support for eligible patients
Assistance navigating the insurance process, including benefits investigations, claims assistance, and information about prior authorizations and appeals.
CareASSIST offers programs and services that can help eligible patients with the cost of ELITEK.
Information on independent support services for patients and caregivers, as well as product ordering and replacement information.
Reference: 1. Cortes J, Moore JO, Maziarz RT, et al. Control of plasma uric acid in adults at risk for tumor lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone—results of a multicenter phase III study. J Clin Oncol. 2010;28(27):4207-4213.